HEPATOLOGY, VOLUME 58, NUMBER 4 (SUPPL)AASLD ABSTRACTS349A
Nathan Davies - Patent Held/Filed: UCL
Rajiv Jalan - Consulting: Ocera Therapeutics, Conatus
The following people have nothing to disclose: Karla C. Lee, Luisa Baker, AnneRiddell, Paola Giordano, Pamela Leckie, Hatim Alibhai, Pratima Chowdary,Rajeshwar Mookerjee, Banwari Agarwal
285
Alpha-Glutathione-S-transferase: A more robust hepaticenzyme for monitoring liver injury
Ian Maina1, Jody A. Balko1, Frank H. Wians2, Michael Poirier3,William M. Lee1; 1Internal Medicine, University of Texas South-western Medical Center, Dallas, TX; 2LoneStar Pathology Labora-tory and Scientific Writing Consultants, Helotes, TX; 3Qualigen,Inc., Carlsbad, CA
Background: Serum alanine and aspartate aminotransferases(AST/ALT) have been the gold standard for detection and quan-titation of liver injury for over six decades, but have relativelylong half-lives (t1/2) (literature estimates ~17 and 47 hrs,respectively) and thus do not reflect immediate changes in liverinjury or recovery. A new point-of-care immunoassay for α-glu-tathione S-transferase (αGST) measures this cytosolic liverenzyme with a predicted t1/2 of 60-90 minutes based on pre-liminary studies and might enable earlier detection of improv-ing or worsening liver injury than conventional enzyme testing.Methods: Daily sera from 31 patients enrolled in the Acute LiverFailure Study Group, with acetaminophen toxicity (APAP), drug-induced liver injury (DILI), ischemic hepatopathy, or autoim-mune hepatitis were analyzed to determine αGST t1/2 andcompared to t1/2 for AST and ALT. αGST values were deter-mined using the Qualigen FastPack® (Carlsbad, CA), a chemi-luminescent immunoassay utilizing a paramagnetic particlematrix with an upper limit of normal (ULN) of 11 ng/mL. ASTand ALT ULN = 40 IU/L. The t1/2 for αGST, AST, and ALT werecalculated from the peak value using an exponential trend lineequation of the serial values. Results: Median αGST for all eti-ologies except DILI were elevated on Day 1 and normalized byDay 3. However, median AST and ALT values did not normal-ize by Day 7. The median t1/2 for αGST, AST, and ALT were:6.4, 22.2, and 33.9 hrs, respectively. Figure 1 represents a sin-gle APAP case. t1/2 calculated using exponential equationsshown were 7.31 hrs, 9.84 hrs, and 29.01 hrs for αGST, AST,and ALT, respectively. Conclusion: αGST is a more responsivemarker of liver injury/recovery allowing for real time assess-ment of improvement or worsening of liver disease and thusmay be of more value than conventional liver enzymes in deter-mining outcome in patients with acute liver failure.
Disclosures:
Michael Poirier - Management Position: Qualigen, Inc.; Patent Held/Filed: Quali-gen, Inc.; Stock Shareholder: Qualigen, Inc.
William M. Lee - Consulting: Eli Lilly, Novartis; Grant/Research Support: Gilead,Roche, Vertex, BI, Anadys, BMS, merck; Speaking and Teaching: MerckThe following people have nothing to disclose: Ian Maina, Jody A. Balko, FrankH. Wians
286
A Dynamic Model for Predicting Outcome in Patientswith HBV Related Acute-On-Chronic Liver Failure
Wei Lin1, Chenggang Jin2, Xiaohui Liu1, Jinqiu He3, Ming Li4,Shuqin Zhang5, Yuexin Zhang6, Hong Chen7, Changqing Zhang8,Lixia Ma1, Xinhuan Wei1, Haiqing Guo1, Zhen Li2, Wenfang Wu9,Jinhua Hu10, Qinghua Meng1, Huiguo Ding1, Yu Chen1, SujunZheng1, Shuang Liu1, Jing Zhang1, Zhongping Duan1; 1BeijingYouan Hosptial,Capital Medical University, Beijing, China; 2BeijingNormal University, Beijing, China; 3The Ninth Hospital of Nan-chang, Nanchang, China; 4The Second People’s Hospital ofFuyang, Fuyang, China; 5Hepatobilary Hospital of Jilin Province,Changchun, China; 6The First Teaching Hospital of Xinjiang Med-ical University, Wulumuqi, China; 7The First Affiliated Hospital ofLanzhou University, Lanzhou, China; 8The Sixth People’s Hospital ofKaifeng, Kaifeng, China; 9Capital Medical University, Beijing,China; 10302 Military Hospital, Beijing, China
Background: Acute-on-chronic liver failure (ACLF) is a fatal syn-drome with rapid progress in months. Most of the existing pre-diction models were based on static baseline variables fromcohort with various etiologies. The aim of the study was to usethe 7-day serial serum biomarker to predict outcome of HBVrelated ACLF. Design: This was a prospective, multicenter,observational study. The predication model was establishedbased on hospitalized HBV-ACLF patients from 7 hospitals.Thereafter the model was validated in another 74 HBV-ACLFcohorts. All the patients fulfilled the diagnosis criteria ofAPASAL “ACLF consensus recommendations” (2010). Theywere all serum HBsAg positive and treated with nucleosideanalogs as standard therapy. The primary endpoint was mor-tality at 12th week. The dynamic model was constructed basedon the change of variables over 7 days with logistic regressionmethod by SPSS17.0.Results: 274 cases were screened and205 cases were enrolled to the study as derivation cohort. Ofthe 205 HBV-ACLF patients, 171 (83.4%) were male, medianage was 41.2 years. 46.8% was Anti-HBe positive. Themedian HBV DNA level was 5.7(0~8.9)×log10 IU/ml.90(43.9%) cases were treated by entecavir(ETV), the otherswere treated by lamivudine(LAM). The overall 12-week mortal-ity was 23.9% with median survival period 25.9 days. The 12-week mortality in ETV group and LAM group was 25.2% and22.2% respectively(P=0.742). Four variables were selected asprediction factors: serum total bilirubin (TBil, μmol/L), plateletcount (PLT, 109/L), prothrombin activity (PTA, %), Anti-HBe (pos-itive=1, negative=0). The model was developed with the valueson baseline and their evolution on the 7th day. The dynamicHBV-ACLF model was: -1.515+ 0.007×TBil +0.004×evolutionin TBil - 0.057×PTA - 0.028×evolution in PTA -0.013×PLT+1.271×Anti-HBe. The model demonstrated improved predic-tion with an area under the receiver operator characteristiccurve (AUC) of 0.856 (cutoff:-0.730; sensitivity:67.3%; speci-ficity: 91.0%), which was superior to the MELD (AUC: 0.579)and the MELD-Na (AUC: 0.624), even when their 7-day serialvalues were taken into consideration (AUC=0.676 and 0.669respectively), all p< 0.01. In the validation cohort, the per-formance of the dynamic HBV-ACLF model (AUC=0.881) alsoshowed superior to MELD (AUC: 0.782) and the MELD-Na(0.761) (all p< 0.01).Conclusion: The present dynamic predic-tion model can achieve a better prediction of the 12-week out-
The n e w e ng l a n d j o u r na l of m e dic i n e review article CRITICAL CARE MEDICINE Acute Liver Failure cute liver failure is a...
Gene Therapy for Acute Liver Failure Current Gene Therapy, 2010, Vol. 10, No. 2 157 tential therapeutic targets involved in the pathogenesis of ALF in...
Liver failure Hyper - acute liver failure Acute liver failure Greatest risk of cerebral oedema, CVS failure Greatest chance of spontaneous survival Sub - ...
If acute liver failure due to a pregnancy-related cause (such as acute fatty liver of pregnancy) is a possible differential diagnosis, urgent delivery of...
APASL Acute-on-chronic liver failure_临床医学_医药卫生_专业资料 暂无评价0人阅读0次下载举报文档 APASL Acute-on-chronic liver failure_临床医学_医药卫生...
PFIC type III in infant presenting as acute liver cell failure 2010_临床医学_医药卫生_专业资料。case report PFIC type III in infant presenting as acute ...
Acute Renal Failure_基础医学_医药卫生_专业资料。Acute Renal Failure ? Definition...after restoration of hepatic function after liver transplantation Type I HRS...
哪几肝衰竭分为急性肝衰竭(acute liver failure, ALF) ,亚急性肝衰竭(subacute liver failure, SALF)和慢性肝衰竭(chronic liver failure, CLF) 。 急性肝衰竭 ...
pregnancy, AFLP)是妊娠晚期特发的严重肝脏损害又名为妊娠期 特发性脂肪肝(Idiopathic acute fatty liver of pregnancy)或妊娠期急性肝衰竭(acute liver failure) ...
急性肝衰竭的处理(AASLD 指导意见) 王宇明 晏泽辉 导言 《急性肝衰竭(acute liver failure, ALF)的处理》的推荐意见建立在一种证据分级的标准上。 作者采用了...
热门文档